Adlai Nortye Ltd. ADR (ANL) AI Stock Analysis

Adlai Nortye Ltd. is a clinical-stage biotechnology company focused on developing cancer treatments, operating across the United States and Mainland China. Its lead drug candidate, AN2025, is a pan-phosphoinositide 3-kinase inhibitor currently in Phase III clinical trials for recurrent or metastatic head and neck squamous cell carcinomas. Its clinical pipeline also includes AN0025, a small molecule prostaglandin E receptor 4 antagonist in Phase Ib trials for multiple oncology indications, and AN4005, an oral small-molecule PD-L1 inhibitor in Phase I testing. Additionally, the company is advancing preclinical candidates AN8025, AN1025, and AN9025.

Adlai Nortye's revenue was $45.7M in FY2021 before declining to $5.0M in FY2023 and remaining flat at $5.0M in FY2025, reflecting a 2-year revenue CAGR of -66.9%. Operating losses have persisted, with operating margins at -18.9% in FY2021, -1452.3% in FY2023, and -714.0% in FY2025. Net income was -$56.7M in FY2021, -$109.2M in FY2023, and -$35.5M in FY2025, accompanied by diluted EPS of -$1.17 in FY2025. Over the trailing twelve months ended June 30, 2026, revenue stood at $18.1M, with quarterly revenue growth increasing 178.1% year-over-year. Operating margin for the trailing twelve months was -44.2% and EPS was -$0.66.

As of June 30, 2026, the company held $232.8M in cash and short-term investments alongside $26.7M in total debt, yielding net cash of $206.1M. Liquidity remains supported by a current ratio of 9.55 and a debt-to-equity ratio of 0.12 against shareholders' equity of $214.8M. For FY2025, Adlai Nortye recorded negative operating cash flow of -$33.5M and free cash flow of -$33.7M. Capital expenditures were modest at $187,491 in FY2025, while the 5-year share count change was 99.0%.

Adlai Nortye trades at an enterprise value of $806.2M and a market capitalization of $710.3M. The stock trades at a price-to-sales multiple of 39.3x and an EV-to-revenue multiple of 44.7x, compared to a price-to-sales median of 4.1x for its US-listed Healthcare peers. Its price-to-book multiple is 4.7x. Over the past year, the stock returned 585.1%, outperforming the S&P 500 (SPY) return of 16.8%, while trading 0.8% above its 200-day moving average.

Wall Street sentiment is tracked by 7 analysts, all giving the stock a Strong Buy rating. The mean price target is $29.50, representing an upside of 167.5% from the last close of $11.03. For the fiscal year ending December 31, 2026, analysts estimate revenue of $17.2M and EPS of -$0.18. For the following fiscal year, 7 analysts project revenue to drop 55.5% to $7.6M with EPS of -$0.29. Adlai Nortye has recorded 0 EPS beats over the last 4 quarters.

This page is an AI-written research summary of Adlai Nortye Ltd. ADR (ANL). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: ANL income statement, ANL balance sheet, ANL key metrics, ANL analyst forecast, ANL chart. See the ANL stock overview for the latest quote and news.